A Phase 2/3 interventional study of BreatheMAX breathing device in Lung Disease, sponsored by Khon Kaen University. Status unknown at 1 site in Thailand. Open to participants aged 15 Years to 85 Years. Per ClinicalTrials.gov, last updated 2010-03-23.
Sponsored by Khon Kaen University · Phase 2/3, Interventional, and Treatment
The purpose of this study is to determined effects of BreatheMAX on secretion clearance.
3,303 studies on the registry are indexed under Lung Diseases; 355 are open to participants now.
This study's planned enrollment of 14 is below the median of 72 across 2,118 interventional studies indexed under Lung Diseases.
Browse Lung Diseases studies →Khon Kaen University is the lead sponsor of 160 studies on the registry; 24 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
BreatheMAX breathing device is Water pressure Threshold Bottle. The level of water in the cylinder determines the load for treatment. In the treatment using 20% PNIP (Peak negative inspiratory pressure) was performed with 6-10 breaths/set; 10 set/day
Device: BreatheMAX breathing device
secretion clearance, breathing exercise
secretion wet weight (gram)
Airway mucus secretion was collected for three hours before and ten hours after treatment based on an auditory airway secretion sound and collected again at 02.00-07.00 am.The mucus secretion was collected by sterile suctioning technique via tracheostomy tube without adding any saline or sterile water.
Time frame: Three hours before, ten hours after treatment and night-time (02.00-07.00 am.)
viscosity of secretion
The secretion were collected in three hours before and after treatment, It were measured viscosity by First The mucus was gently homogenized by tissue grinder 5 ml (Cw11-205, Cowie, UK) for six minute at 37 degree celsius Second using Micro-Oswald viscometers with a capillary diameter of 0.77 mm for viscosity measure at same temperature in each sample(before and after).
Time frame: Three hours before and after treatment
Heart rate (beat/min)
Heart rate was monitored before, during and immediate after breathing exercise with BreatheMAX (6-10 beats/set, 10 set/day and rest between ste for 1 minute)
Time frame: Before, during breathing exercise with device and immediate after treatment
Oxygen saturation (%SpO2)
Oxygen saturation was monitored before, during and immediate after breathing exercise with BreatheMAX (6-10 beats/set, 10 set/day and rest between set for 1 minute)
Time frame: Before, during breathing exercise with device and immediate after treatment
Respiratory rate (times/min)
Respiratory rate was measured by manual for 1 minute before, rest interval between set and immediate after breathing exercise with device (during the patients reconnection mechanical ventilation)
Time frame: In rest interval between set (1 minute)
This study is status unknown, as verified in Jan 2010. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Khon Kaen University